

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Dextroamphetamine Transdermal System (Xelstrym)

Notes:

- Quantity Limits: Yes
- ** Adequate trial of a long-acting agent is further defined as wearing off that is not resolved by increasing the dose, AND adding a short-acting agent OR increasing frequency to twice daily OR clinically significant side effects related to the dosage form that cannot be resolved by adjusting the dose or timing
- **Initiation (new start) criteria:** Non-formulary **dextroamphetamine transdermal system (Xelstrym)** will be covered on the prescription drug benefit when the following criteria are met:
 - Patient has a diagnosis of attention deficit and hyperactivity disorder
 - Patient has failed an adequate trial[^] of long-acting amphetamine salt combo or patient has an allergy or intolerance* to amphetamine
 - Patient has failed an adequate trial[^] of long-acting methylphenidate or patient has an allergy or intolerance* to methylphenidate
 - Patient has failed an adequate trial[^] of long-acting dextroamphetamine, unless patient is unable to swallow whole tablets or tolerate sprinkles

-OR-

- Patient is under 21 years of age
- Patient has a diagnosis of attention deficit and hyperactivity disorder
- Patient has failed an adequate trial[^] of long-acting dextroamphetamine, unless patient is unable to swallow whole tablets or tolerate sprinkles

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary **dextroamphetamine transdermal system (Xelstrym)** will be covered on the prescription drug benefit when the following criteria are met:

- Patient has a diagnosis of attention deficit and hyperactivity disorder
- Patient has failed an adequate trial[^] of long-acting dextroamphetamine, unless patient is unable to swallow whole tablets or tolerate sprinkles

-OR-

- Patient is under 21 years of age